The stock of Insys Therapeutics Inc (NASDAQ:INSY) is a huge mover today! About 463,514 shares traded hands. Insys Therapeutics Inc (NASDAQ:INSY) has declined 42.15% since April 4, 2016 and is downtrending. It has underperformed by 43.24% the S&P500.
The move comes after 7 months positive chart setup for the $717.62 million company. It was reported on Nov, 4 by Barchart.com. We have $13.22 PT which if reached, will make NASDAQ:INSY worth $157.88M more.
Insys Therapeutics Inc (NASDAQ:INSY) Ratings Coverage
Out of 4 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Insys Therapeutics has been the topic of 9 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The rating was maintained by Jefferies with “Buy” on Thursday, August 4. Jefferies maintained the stock with “Buy” rating in Wednesday, February 24 report. JMP Securities maintained Insys Therapeutics Inc (NASDAQ:INSY) on Wednesday, March 9 with “Market Outperform” rating. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, September 22. Jefferies maintained the stock with “Buy” rating in Monday, October 10 report. The stock of Insys Therapeutics Inc (NASDAQ:INSY) has “Buy” rating given on Friday, August 14 by Zacks. The rating was maintained by Jefferies with “Buy” on Tuesday, April 12. Janney Capital initiated Insys Therapeutics Inc (NASDAQ:INSY) rating on Thursday, April 14. Janney Capital has “Buy” rating and $22 price target. On Tuesday, August 4 the stock rating was maintained by Oppenheimer with “Hold”.
According to Zacks Investment Research, “Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona.”
Insitutional Activity: The institutional sentiment decreased to 0.7 in Q2 2016. Its down 0.36, from 1.06 in 2016Q1. The ratio turned negative, as 22 funds sold all Insys Therapeutics Inc shares owned while 42 reduced positions. 13 funds bought stakes while 32 increased positions. They now own 31.30 million shares or 9.76% less from 34.69 million shares in 2016Q1.
Schwab Charles Mgmt last reported 0% of its portfolio in the stock. Financial Bank Of America Corporation De accumulated 13,125 shares or 0% of the stock. Adage Cap Gp Ltd Limited Liability Company last reported 0.01% of its portfolio in the stock. Pictet Asset Mngmt accumulated 0.01% or 87,426 shares. Bnp Paribas Arbitrage Sa has invested 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY). Susquehanna Int Llp holds 89,427 shares or 0% of its portfolio. Credit Agricole S A accumulated 0.01% or 192,000 shares. Rock Springs Mngmt Lp accumulated 0.35% or 365,500 shares. Clinton Grp holds 0.01% or 17,368 shares in its portfolio. Victory Capital Mngmt owns 3,313 shares or 0% of their US portfolio. Geode Limited Company last reported 0% of its portfolio in the stock. Bessemer Inc holds 0% or 5,400 shares in its portfolio. The Maryland-based Proshare Advsr Limited Liability Corporation has invested 0.01% in Insys Therapeutics Inc (NASDAQ:INSY). Wellington Management Group Inc Llp holds 0% or 125,405 shares in its portfolio. Commerzbank Aktiengesellschaft Fi accumulated 0% or 31,941 shares.
Insider Transactions: Since May 11, 2016, the stock had 2 buys, and 4 selling transactions for $170,592 net activity. The insider STANLEY THEODORE H sold $260,320. The insider BRENNAN DANIEL sold $110,752. $641,827 worth of Insys Therapeutics Inc (NASDAQ:INSY) was bought by JOHN N KAPOOR TRUST DATED SEPTEMBER 20 1989 on Wednesday, May 11. FOURTEAU PATRICK also sold $276,900 worth of Insys Therapeutics Inc (NASDAQ:INSY) shares.
Another recent and important Insys Therapeutics Inc (NASDAQ:INSY) news was published by Forbes.com which published an article titled: “Insys Therapeutics Pops On Earnings Beat, But Revenues Plunge” on November 03, 2016.
INSY Company Profile
Insys Therapeutics, Inc., incorporated on June 15, 1990, is a commercial-stage specialty pharmaceutical company. The Firm develops and commercializes supportive care products. Subsys is the Company’s marketed product. Subsys is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and is a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Firm markets Subsys through its field sales force focused on supportive care physicians in the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.